ResearcherNagoya UniversityActive in the last 2 years
Keizo Fujita
Matched on ORCID iD 0000-0003-4111-9852; OpenAlex author ID A5046172068. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2024: 1 paper · 2025: 1 paper · 2026: 3 papers
Papers 5
- High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
- ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. Co-author DOI 10.1245/s10434-026-19112-3↗
- ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
- Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Rec… Co-author DOI 10.1097/mpa.0000000000002446↗
- Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. Co-author DOI 10.21873/anticanres.17297↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mitsuro Kanda · 4 shared papers, 2024–2026 · strength 1.02
- Paper ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. DOI 10.1245/s10434-026-19112-3↗
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Masamichi Hayashi · 4 shared papers, 2024–2026 · strength 1.02
- Paper ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. DOI 10.1245/s10434-026-19112-3↗
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Tomohisa Otsu · 4 shared papers, 2024–2026 · strength 0.85
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Paper Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Na… DOI 10.1097/mpa.0000000000002446↗
- Nobuhiko Nakagawa · 4 shared papers, 2024–2026 · strength 0.85
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Paper Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Na… DOI 10.1097/mpa.0000000000002446↗
- Ryo Ashida · 3 shared papers, 2026 · strength 0.84
- Paper ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. DOI 10.1245/s10434-026-19112-3↗
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Shinji Mii · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Junpei Yamaguchi · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Yukihiro Yokoyama · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
- Paper High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. DOI 10.1245/s10434-025-18912-3↗
- Paper ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhance… DOI 10.1245/s10434-026-19134-x↗
- Yasuhiro Kodera · 2 shared papers, 2024–2025 · strength 0.40
- Paper Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Na… DOI 10.1097/mpa.0000000000002446↗
- Paper Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of thei… DOI 10.21873/anticanres.17297↗
- Yukiyasu Okamura · 1 shared paper, 2026 · strength 0.39
- Atsushi Enomoto · 1 shared paper, 2026 · strength 0.22
- Mitsuru Tashiro · 1 shared paper, 2025 · strength 0.22
- Masahiro Nakatochi · 1 shared paper, 2025 · strength 0.22
- Norifumi Hattori · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.